Aiste Dijokaite-Guraliuc

May 8, 2024 | cell.com | Chang Liu |Daming Zhou |Aiste Dijokaite-Guraliuc

Highlights•BA.2.86, highly mutated from BA.2, is mapped in the landscape of recent variants•It is marginally less evasive than XBB.1.5 but escapes a panel of BA.2 antibodies•It has increased affinity for ACE2, possibly aiding transmission•Its RBD is primed for further escape at residues 455 and/or 456, as seen in JN.1SummaryBA.2.86, a recently described sublineage of SARS-CoV-2 Omicron, contains many mutations in the spike gene.

Apr 15, 2024 | nature.com | Chang Liu |Aiste Dijokaite-Guraliuc |Daming Zhou |Alexander J. Mentzer |Thomas Ritter |Nigel Temperton | +8 more

AbstractThe rapid evolution of SARS-CoV-2 is driven in part by a need to evade the antibody response in the face of high levels of immunity. Here, we isolate spike (S) binding monoclonal antibodies (mAbs) from vaccinees who suffered vaccine break-through infections with Omicron sub lineages BA.4 or BA.5. Twenty eight potent antibodies are isolated and characterised functionally, and in some cases structurally.

Mar 27, 2024 | nature.com | Daming Zhou |Aiste Dijokaite-Guraliuc |Alexander J. Mentzer |Nigel Temperton |Paul Klenerman |Susanna J. Dunachie | +3 more

AbstractUnder pressure from neutralising antibodies induced by vaccination or infection the SARS-CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all mAbs developed for clinical use. Most potent antibodies bind to the receptor binding domain which has become heavily mutated.